0000000000016348

AUTHOR

Natasha B. Leighl

showing 2 related works from this author

A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced o…

2019

Purpose This study investigated the safety and clinical activity of lumretuzumab, a humanised antihuman epidermal growth factor receptor 3 (HER3) monoclonal antibody, in combination with carboplatin and paclitaxel in first-line treatment of patients with squamous non-small cell lung cancer (sqNSCLC). HER3 ligand heregulin and HER3 protein expression were evaluated as potential biomarkers of clinical activity. Patients and methods This open-label, phase Ib/II study enrolled patients receiving lumretuzumab at 800 mg (flat) in combination with carboplatin (area under the curve (AUC) 6 mg/mL×min) and paclitaxel (200 mg/m 2) administered intravenously on a every 3-week schedule. Adverse event (A…

Cancer Researchnon-small cell lung cancer (NSCLC)phase ilcsh:RC254-282chemistry.chemical_compoundErbB3heregulinMedicineERBB3Epidermal growth factor receptor1506squamousOriginal Researchbiologybusiness.industryArea under the curveLumretuzumabmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCarboplatinnon-small cell lung cancer (NSCLC)OncologychemistryPaclitaxelhuman epidermal growth factor receptor 3 (HER3)Cancer researchbiology.proteinNeuregulinbiomarkerbusinessESMO open
researchProduct

Safety and efficacy of buparlisib (BKM120) and chemotherapy in advanced, squamous non-small cell lung cancer (sqNSCLC): Results from the phase Ib/II …

2016

e20522Background: Phosphatidylinositol 3-kinase (PI3K) pathway activation may contribute to primary and secondary resistance to platinum (Pt)-based chemotherapy (CT) in sqNSCLC. The pan-PI3K inhibi...

0301 basic medicineBasaltCancer ResearchChemotherapybusiness.industrymedicine.medical_treatmentBuparlisib03 medical and health scienceschemistry.chemical_compound030104 developmental biology0302 clinical medicineOncologychemistry030220 oncology & carcinogenesisSquamous non-small cell lung cancerCancer researchmedicinePhosphatidylinositolbusinessPI3K/AKT/mTOR pathwayJournal of Clinical Oncology
researchProduct